Does simponi cause cancer?

See the DrugPatentWatch profile for simponi

How does Simponi affect cancer risk?

Simponi contains golimumab, a TNF inhibitor that suppresses immune system activity. TNF inhibitors can raise the risk of certain cancers because they weaken the immune system's ability to detect and destroy abnormal cells. Studies show an increased incidence of lymphoma and other malignancies in patients taking TNF blockers.

Does Simponi raise the risk of skin cancer?

Patients on Simponi may face a higher risk of skin cancers, especially non-melanoma types. The FDA requires a black box warning for malignancy risk with TNF inhibitors, and clinical trials reported skin cancers as common adverse events.

When does cancer risk appear during treatment?

Cancer cases often develop after prolonged use rather than immediately. Many reports link TNF inhibitor exposure to malignancies diagnosed after months or years of treatment. Data from registries tracking TNF blockers suggest the risk increases with duration of exposure.

What patient factors raise cancer risk further?

Older patients, smokers, and those already diagnosed with cancer or chronic infections like hepatitis B are more vulnerable. People with a history of skin cancer should discuss alternatives with their doctor before starting Simponi.

How does Simponi compare with other TNF inhibitors?

Risk profiles across TNF inhibitors like Humira, Enbrel, and Simponi appear similar based on class effects. Registry data and FDA adverse event reports show comparable rates of lymphoma and skin cancer across the TNF blocker group.

What happens if cancer develops on Simponi?

Doctors usually discontinue Simponi immediately if a patient develops cancer. Treatment plans then shift to managing the cancer along with the underlying inflammatory condition that originally needed the TNF inhibitor.

Can biosimilars of Simponi cause cancer?

Biosimilars contain the same active ingredient as the originator version. They share the same black box warning and clinical data profile for malignancy risk, so the risk profile remains unchanged.

What does the black box warning say?

The black box warning on Simponi highlights increased risk of serious infections and malignancies, including lymphoma and skin cancer. It advises providers to monitor patients closely and screen for cancer before and during treatment.

When does the Simponi patent expire?

The compound patent on golimumab expires in 2027. [1]